

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Anti-Human IL-17 (IL-17A) Antibody, Goat, Polyclonal ABT-ABG10217-U050

Article Name	Anti-Human IL-17 (IL-17A) Antibody, Goat, Polyclonal
Biozol Catalog Number	ABT-ABG10217-U050
Supplier Catalog Number	ABG10217-U050
Alternative Catalog Number	ABT-ABG10217-U050-50UG
Manufacturer	Abcepta
Host	Goat
Category	Antikörper
Application	ELISA, IHC, WB
Species Reactivity	Human
Clonality	Polyclonal
Purity	Produced from sera of goats pre-immunized with highly pure (>98%) recombinant hIL-17A. Anti-Human IL-17A specific antibody was purified by affinity chromatography employing immobilized hIL-17 matrix.
Form	A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.
Antibody Type	Polyclonal Antibody

Application Notes

WesternBlot: To detect hIL-17A by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-17A is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.. **Sandwich:** To detect hIL-17A by sandwich ELISA (using 100 µl/well antibody solution) a concentration of 0.5 - 2.0 µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems Biotinylated Anti-Human IL-17A (60-017AGBT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-17A..

Immunohistochemistry: This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.125 µg/ml - 0.25 µg/ml with an overnight incubation at 4C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary. Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute..

Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of Human IL-17A (50.00 ng/ml), a concentration of 0.43 - 0.65 µg/ml of this antibody is required..

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.